Avosentan
| CAS No. | 290815-26-8 | Cat. No. | BCP28417 |
| Name | Avosentan | ||
| Synonyms | SPP301; SPP301; SPP301; RO 67-0565; RO-67-0565; RO67-0565; R-639; | ||
| Formula | C23H21N5O5S | M. Wt | 479.5 |
| Description | Avosentan is an endothelin receptor antagonist. Avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention. Avosentan reduces albuminuria when added to standard treatment in people with type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure. | ||
| Pathways | GPCR/G Protein | ||
| Targets | Endothelin Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.